Home » Stocks » TARO

Taro Pharmaceutical Industries Ltd. (TARO)

Stock Price: $73.55 USD 0.48 (0.66%)
Updated Jun 21, 2021 12:04 PM EDT - Market open
Market Cap 2.80B
Revenue (ttm) 548.97M
Net Income (ttm) -386.65M
Shares Out 38.26M
EPS (ttm) -10.12
PE Ratio n/a
Forward PE 19.05
Dividend n/a
Dividend Yield n/a
Trading Day June 21
Last Price $73.55
Previous Close $73.07
Change ($) 0.48
Change (%) 0.66%
Day's Open 73.64
Day's Range 73.00 - 74.79
Day's Volume 9,057
52-Week Range 53.95 - 80.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Provides Results for the Year Ended March 31, 2021

1 month ago - Business Wire

Taro Pharmaceutical Indus (NYSE:TARO) unveils its next round of earnings this Wednesday, May 19. Here is Benzinga's everything-that-matters guide for the earnings announcement.

1 month ago - Benzinga

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro to Announce Full Year Results on May 19, 2021

1 month ago - Business Wire

Taro Pharmaceutical Industries Ltd. (TARO) CEO Uday Baldota on Q2 2021 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

Taro (TARO) delivered earnings and revenue surprises of 53.25% and 14.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Taro (TARO) delivered earnings and revenue surprises of -34.48% and -25.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research

Here's why a new initiative by the FDA to reduce drug prices is great for patients but should raise the alarm among pharmaceutical investors.

Other stocks mentioned: ANIP, LCI, MYL, PFE, TEVA
1 year ago - The Motley Fool

Value investors like companies with strong balance sheets and no debt; it means there are no worries about the company going broke or getting into serious financial trouble.

1 year ago - GuruFocus

Taro Pharmaceutical Industries Ltd.'s (TARO) CEO Uday Baldota on Q4 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Taro (TARO) delivered earnings and revenue surprises of -7.19% and 3.98%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Taro Pharmaceutical Industries Ltd (NYSE: TARO) former Vice President of Sales and Marketing Ara Aprahamian has been indicted by the Justice Department for price-fixing and bid-rigging on Tuesday, Reute...

1 year ago - Benzinga

Taro (TARO) delivered earnings and revenue surprises of 14.29% and -14.14%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Taro Pharmaceutical Industries Ltd. (TARO) CEO Uday Baldota on Q2 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Taro (TARO) delivered earnings and revenue surprises of -15.12% and -4.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Taro (TARO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Taro (TARO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Taro Pharmaceutical (TARO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

1 year ago - Zacks Investment Research

Taro has inherited a top tier balance sheet due to management's refusal to engage in LBOs during the drug acquisition bubble of 2014-2015.

2 years ago - Seeking Alpha

Taro Pharmaceutical Industries Ltd. (TARO) CEO Uday Baldota on Q4 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

Taro (TARO) delivered earnings and revenue surprises of -32.74% and -5.26%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

2 years ago - Zacks Investment Research

About TARO

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprises allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, ... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
1959
CEO
Uday Baldota
Country
Israel
Stock Exchange
NYSE
Ticker Symbol
TARO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for TARO stock is "Buy" and the 12-month stock price forecast is 80.00.

Price Target
$80.00
Analyst Consensus: Buy